[go: up one dir, main page]

PT1669068E - Compounds effecting glucokinase - Google Patents

Compounds effecting glucokinase Download PDF

Info

Publication number
PT1669068E
PT1669068E PT06001809T PT06001809T PT1669068E PT 1669068 E PT1669068 E PT 1669068E PT 06001809 T PT06001809 T PT 06001809T PT 06001809 T PT06001809 T PT 06001809T PT 1669068 E PT1669068 E PT 1669068E
Authority
PT
Portugal
Prior art keywords
glucokinase
compounds effecting
compounds
effecting glucokinase
effecting
Prior art date
Application number
PT06001809T
Other languages
Portuguese (pt)
Inventor
Craig Johnstone
Roger James
Darren Mckerrecher
Scott Boyd
Peter Caulkett
Suzanne Bowker
Roney Hargreaves
Cliford David Jones
Michael Howard Block
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1669068E publication Critical patent/PT1669068E/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/66—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
PT06001809T 2001-08-17 2002-08-15 Compounds effecting glucokinase PT1669068E (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102764A SE0102764D0 (en) 2001-08-17 2001-08-17 Compounds

Publications (1)

Publication Number Publication Date
PT1669068E true PT1669068E (en) 2008-08-20

Family

ID=20285065

Family Applications (5)

Application Number Title Priority Date Filing Date
PT06001809T PT1669068E (en) 2001-08-17 2002-08-15 Compounds effecting glucokinase
PT04028297T PT1568367E (en) 2001-08-17 2002-08-15 Compounds effecting glucokinase
PT06001808T PT1661563E (en) 2001-08-17 2002-08-15 Compound effecting glucokinase
PT06001807T PT1661569E (en) 2001-08-17 2002-08-15 Compounds effecting glucokinase
PT04028298T PT1529530E (en) 2001-08-17 2002-08-15 Compounds affecting glucokinase

Family Applications After (4)

Application Number Title Priority Date Filing Date
PT04028297T PT1568367E (en) 2001-08-17 2002-08-15 Compounds effecting glucokinase
PT06001808T PT1661563E (en) 2001-08-17 2002-08-15 Compound effecting glucokinase
PT06001807T PT1661569E (en) 2001-08-17 2002-08-15 Compounds effecting glucokinase
PT04028298T PT1529530E (en) 2001-08-17 2002-08-15 Compounds affecting glucokinase

Country Status (31)

Country Link
US (3) US7390908B2 (en)
EP (12) EP1674097B1 (en)
JP (2) JP3987829B2 (en)
KR (1) KR100920439B1 (en)
CN (4) CN100577163C (en)
AR (1) AR037898A1 (en)
AT (11) ATE397927T1 (en)
AU (1) AU2002321462B2 (en)
BR (1) BR0212008A (en)
CA (1) CA2457410C (en)
CO (1) CO5560563A2 (en)
CY (5) CY1105746T1 (en)
DE (11) DE60227119D1 (en)
DK (5) DK1661569T3 (en)
ES (10) ES2285341T7 (en)
HU (1) HUP0401213A3 (en)
IL (2) IL160219A0 (en)
IS (1) IS7150A (en)
MX (1) MXPA04001500A (en)
MY (1) MY146279A (en)
NO (1) NO20040686L (en)
NZ (1) NZ531193A (en)
PL (1) PL368970A1 (en)
PT (5) PT1669068E (en)
RU (1) RU2329043C9 (en)
SE (1) SE0102764D0 (en)
SI (5) SI1669068T1 (en)
TW (1) TWI333855B (en)
UA (1) UA83182C2 (en)
WO (1) WO2003015774A1 (en)
ZA (1) ZA200401015B (en)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102300D0 (en) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (en) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (en) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2004123732A (en) * 2002-09-10 2004-04-22 Takeda Chem Ind Ltd Five-membered heterocyclic compound
US7368578B2 (en) 2002-09-10 2008-05-06 Takeda Pharmaceutical Company Limited Five-membered heterocyclic compounds
JP2006509774A (en) 2002-10-03 2006-03-23 ノバルティス アクチエンゲゼルシャフト Substituted (thiazol-2-yl) -amides or sulfonamides as glucokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
PL378117A1 (en) 2003-02-11 2006-03-06 Prosidion Limited Tri(cyclo) substituted amide compounds
AR045414A1 (en) 2003-02-13 2005-10-26 Banyu Pharma Co Ltd DERIVATIVES OF 2 - PIRIDINCARBOXAMIDA AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
NZ541824A (en) 2003-02-26 2010-04-30 Banyu Pharma Co Ltd Heteroarylcarbamoylbenzene derivatives as glucokinase activators
EP1633348B1 (en) 2003-05-02 2008-10-08 Elan Pharmaceuticals, Inc. 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP1635821B1 (en) * 2003-05-02 2009-07-08 Elan Pharmaceuticals, Inc. 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl)amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
ATE390922T1 (en) * 2003-06-20 2008-04-15 Hoffmann La Roche 2-AMINOBENZOTHIAZOLE AS A CB1 RECEPTOR INVERSE AGONIST
ES2222822B1 (en) * 2003-07-28 2005-12-16 Laboratorios Farmaceuticos Rovi, S.A. DIAMIDES OF AMINO ACIDS IN NON-ALFA POSITION USEFUL AS ASSISTANTS FOR THE ADMINISTRATION OF ACTIVE BIOLOGICAL AGENTS.
WO2005046683A1 (en) 2003-10-07 2005-05-26 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
GB0325402D0 (en) * 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
GB0328178D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
US20080312207A1 (en) * 2004-02-18 2008-12-18 Craig Johnstone Compounds
RU2392275C2 (en) * 2004-02-18 2010-06-20 Астразенека Аб Benzamide derivatives and application as glucokinase activation agents
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS
BRPI0509573A (en) 2004-04-02 2007-09-25 Novartis Ag sulfonamide thiazolpyridine derivatives as useful glucokinase activators for the treatment of type 2 diabetes
BRPI0509543A (en) 2004-04-02 2007-09-18 Novartis Ag thiazolopyridine derivatives, pharmaceutical conditions containing them and methods for treating glucokinase-mediated conditions
RU2403246C2 (en) * 2004-06-05 2010-11-10 Астразенека Аб Heteroarylbenzamyl derivatives for application as glucokinase (glk) activators in treatment of diabetes
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR100739367B1 (en) * 2004-07-14 2007-07-16 크리스탈지노믹스(주) Sulfamide derivatives and a composition for promoting fat metabolism containing the same
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
US7700640B2 (en) 2004-10-16 2010-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
CA2609394A1 (en) * 2005-05-23 2006-11-30 Masaki Takagi Pyrazole compound and therapeutic agent for diabetes comprising the same
US20110059941A1 (en) * 2005-05-24 2011-03-10 Peter William Rodney Caulkett 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators
GB0510852D0 (en) * 2005-05-27 2005-07-06 Astrazeneca Ab Chemical compounds
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
EP1910350A1 (en) * 2005-07-09 2008-04-16 AstraZeneca AB 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
JP4651714B2 (en) 2005-07-09 2011-03-16 アストラゼネカ アクチボラグ Heteroarylbenzamide derivatives for use as GLK activators in the treatment of diabetes
GB0514173D0 (en) * 2005-07-09 2005-08-17 Astrazeneca Ab Chemical compounds
RU2415141C2 (en) * 2005-07-09 2011-03-27 Астразенека Аб Heteroarylbenzamide derivatives applied as glk activators in diabetes treatment
ES2426345T3 (en) 2005-07-20 2013-10-22 Eli Lilly And Company Compound bound in 1-amino position
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
JP2007063225A (en) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd Imidazopyridine compound
RU2008112198A (en) 2005-09-29 2009-10-10 Санофи-Авентис (Fr) DERIVATIVES OF PHENYL-1,2,4-OXADIAZAZOLONE, METHODS FOR THEIR PRODUCTION AND THEIR APPLICATION AS PHARMACEUTICAL PRODUCTS
GT200600428A (en) 2005-09-30 2007-05-21 ORGANIC COMPOUNDS
GT200600429A (en) 2005-09-30 2007-04-30 ORGANIC COMPOUNDS
BRPI0618649A2 (en) 2005-11-17 2011-09-06 Lilly Co Eli compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and use of a compound
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
NL2000581C2 (en) * 2006-04-20 2008-01-03 Pfizer Prod Inc Condensed phenylamidoheterocyclic compounds.
EP2019823B1 (en) * 2006-04-28 2010-11-24 TransTech Pharma, Inc. Benzamide glucokinase activators
CA2649577A1 (en) * 2006-04-28 2007-11-08 Transtech Pharma, Inc. Benzamide glucokinase activators
US8211925B2 (en) 2006-04-28 2012-07-03 Transtech Pharma, Inc. Benzamide glucokinase activators
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
UA93548C2 (en) 2006-05-05 2011-02-25 Айерем Елелсі Compounds and compositions as hedgehog pathway modulators
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
US7888504B2 (en) * 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
KR20090025358A (en) 2006-07-24 2009-03-10 에프. 호프만-라 로슈 아게 Pyrazoles as Glucokinase Activators
DK2054049T3 (en) 2006-08-24 2016-08-01 Univ Tennessee Res Found SUBSTITUTED ACYLANILIDES AND PROCEDURES FOR USING THEREOF
JP5296688B2 (en) 2006-09-11 2013-09-25 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト Insecticidal compound
AR063028A1 (en) 2006-10-06 2008-12-23 Banyu Pharma Co Ltd HETEROCICLIC DERIVATIVES OF PIRIDIN-2-CARBOXAMIDE GLUCOKINASE ACTIVATORS, USEFUL FOR THE TREATMENT OF DIABETES AND OBESITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
WO2008044700A1 (en) * 2006-10-11 2008-04-17 Takeda Pharmaceutical Company Limited GSK-3β INHIBITOR
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
CL2007003061A1 (en) * 2006-10-26 2008-08-01 Astrazeneca Ab COMPOUNDS DERIVED FROM 3,5-DIOXI-BENZAMIDA; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT A MEDIUM DISEASE THROUGH GLK, SUCH AS TYPE 2 DIABETES.
UA95815C2 (en) * 2006-10-26 2011-09-12 Астразенека Аб Benzoyl amino heterocyclyl compounds as glucokinase (glk) activators
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
WO2008062739A1 (en) * 2006-11-20 2008-05-29 Japan Tobacco Inc. Pyrazoles and use thereof as drugs
AU2007331471C1 (en) * 2006-12-15 2013-07-25 Glaxo Group Limited Benzamide derivatives as EP4 receptor agonists
JP5419706B2 (en) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド Glucokinase activator
JP2010513445A (en) * 2006-12-21 2010-04-30 アストラゼネカ アクチボラグ Novel crystalline compounds useful as GLK activators
EP2079694B1 (en) 2006-12-28 2017-03-01 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
WO2008104994A2 (en) 2007-02-28 2008-09-04 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8299115B2 (en) 2007-06-08 2012-10-30 Debnath Bhuniya Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
JP2010529203A (en) * 2007-06-11 2010-08-26 ブリストル−マイヤーズ スクイブ カンパニー 1,3-dihydroxy-substituted phenylamide glucokinase activator
CN101835765B (en) * 2007-08-03 2013-05-29 罗马克实验室有限公司 Alkylsulfonyl-substituted thiazolide compounds
TW200922582A (en) * 2007-08-20 2009-06-01 Organon Nv N-benzyl, N'-arylcarbonylpiperazine derivatives
US8314091B2 (en) 2007-08-20 2012-11-20 Msd Oss B.V. N-benzyl,N'-arylcarbonylpiperazine derivatives
US9340506B2 (en) 2007-10-08 2016-05-17 Advinus Therapeutics Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
ES2446932T3 (en) * 2007-10-08 2014-03-10 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their procedure and applications in medicine
EA201000561A1 (en) * 2007-10-09 2010-10-29 Мерк Патент Гмбх PYRIDINE DERIVATIVES, SUITABLE AS GLUKOKINASE ACTIVATORS
BRPI0818348A2 (en) 2007-10-09 2015-04-07 Merck Patent Ges Mit Beschränkter Haftung N- (PIRAZOL-3-IL) -BENZAMIDE DERIVATIVES AS GLUCKINASE ACTIVATORS
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
CN112079769A (en) 2008-04-23 2020-12-15 里格尔药品股份有限公司 Carboxamide compounds for the treatment of metabolic disorders
KR101006311B1 (en) * 2008-06-27 2011-01-06 김정이 Loess thermal mat using hot water and its manufacturing method
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2324028A2 (en) 2008-08-04 2011-05-25 AstraZeneca AB Therapeutic agents 414
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009314200B2 (en) 2008-11-17 2011-11-17 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
US20100221505A1 (en) 2009-01-26 2010-09-02 Nanolnk, Inc. Large area, homogeneous array fabrication including homogeneous substrates
WO2010085768A1 (en) 2009-01-26 2010-07-29 Nanoink,Inc. Large area, homogeneous array fabbrication including leveling with use of bright spots
EP2389615A1 (en) 2009-01-26 2011-11-30 Nanoink, Inc. Large area, homogeneous array fabrication including substrate temperature control
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
WO2010116177A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
AR076221A1 (en) * 2009-04-09 2011-05-26 Astrazeneca Ab DERIVED FROM PIRAZOL [4,5-E] PYRIMIDINE AND ITS USE TO TREAT DIABETES AND OBESITY
AP3074A (en) 2009-05-12 2014-12-31 Romark Lab Lc Haloalkyl heteroaryl benzamide compounds
PT2445349T (en) 2009-06-26 2022-05-16 Romark Laboratories Lc Compounds and methods for treating influenza
WO2011011508A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
CN102482267B (en) * 2009-07-31 2014-12-03 卡迪拉保健有限公司 Substituted benzamide derivatives as glucokinase (GK) activators
WO2011081280A2 (en) * 2009-09-22 2011-07-07 Yuhan Corporation Novel glucokinase activators and processes for the preparation thereof
MX2012003377A (en) * 2009-09-25 2012-05-08 Bayer Cropscience Ag N-(1,2,5-oxadiazol-3-yl) benzamides and the use thereof as herbicides.
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
JP2013522294A (en) * 2010-03-18 2013-06-13 タケダ カリフォルニア インコーポレイテッド Process for producing 2-amino-5-fluorothiazole
WO2011135355A1 (en) 2010-04-29 2011-11-03 Astrazeneca Ab 3-{ [5 -(azetidin-1-ylcarbonyl)pyrazin-2 -yl] oxy} -5-{ [(1s) -2 -hydroxy- 1 -methylethyl]oxy} -n- (5 -methylpyrazin-2-) benzamid monohydrate
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP5769326B2 (en) * 2010-10-19 2015-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Rho kinase inhibitor
CN103269593A (en) * 2010-11-01 2013-08-28 罗马克实验室有限公司 Alkylsulfinyl-ubstituted thiazolide compounds
BR112013021236B1 (en) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp benzimidazole derivative compound, and, composition
US20150057220A1 (en) 2012-04-16 2015-02-26 Kaneq Pharma Inc. Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors
KR102122941B1 (en) 2012-07-13 2020-06-15 지티엑스, 인코포레이티드 A method of treating androgen receptor(ar)-positive breast cancers with selective androgen receptor modulator(sarms)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN102942541B (en) * 2012-12-04 2014-07-23 西北师范大学 Receptor compound as well as synthesis and application of receptor compound in colorimetric detection of fluorine ions
MX2015010935A (en) 2013-02-22 2015-10-29 Merck Sharp & Dohme Antidiabetic bicyclic compounds.
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
EP2970281A4 (en) * 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BENZENE COMPOUNDS
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN104672219A (en) * 2015-02-13 2015-06-03 佛山市赛维斯医药科技有限公司 Glucokinase activators containing glucosamide structure and application thereof
CN104672218A (en) * 2015-02-13 2015-06-03 佛山市赛维斯医药科技有限公司 Glucokinase activator containing glucosamide structure, preparation method and application of glucokinase activator to treatment of type II diabetes mellitus
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
EP3601250A4 (en) * 2017-03-27 2020-11-25 Pharmakea, Inc. Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
CN110606831A (en) * 2018-06-14 2019-12-24 上海度德医药科技有限公司 Novel intermediate of Icalaprim and preparation method and application thereof
CN109879818A (en) * 2019-04-04 2019-06-14 安徽丰乐农化有限责任公司 The synthetic method of N- (4,6- dimethoxypyridin -2- base) -4- methylsulfonyl -2- nitrobenzamide
CN114340734A (en) * 2019-06-24 2022-04-12 博善人工智能生物科技有限公司 New compounds and methods
KR102138149B1 (en) * 2019-08-29 2020-07-27 솔브레인 주식회사 Growth inhibitor for forming thin film, method for forming thin film and semiconductor substrate prepared therefrom
CN114591192B (en) * 2020-12-04 2024-06-21 江西仰立新材料有限公司 A preparation method of N-cyclopropylmethylaniline compounds
CN119639021B (en) * 2024-12-27 2025-10-21 常州大学 A type of dendrimer supramolecular gelator and its application

Family Cites Families (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2750393A (en) * 1954-12-01 1956-06-12 Sterling Drug Inc Iodinated 5-henzamidotetrazoles and preparation thereof
US2967194A (en) * 1958-05-15 1961-01-03 Pennsalt Chemicals Corp 4-trifluoromethylsalicylamides
FR1526074A (en) 1967-03-22 1968-05-24 Rech S Ind S O R I Soc D Methoxy-phenyl-amino-2-thiazoles, their amides and processes for their preparation
FR2088019A1 (en) 1970-05-08 1972-01-07 Rabot Ets David Esters of 2 and 6-substituted nicotinic acids - with vasomotor active
GB1352415A (en) 1970-05-03 1974-05-08 Boots Co Ltd Esters of substituted nicotine acids
CS173097B1 (en) 1972-12-01 1977-02-28
GB1400540A (en) 1972-12-06 1975-07-16 Smith Kline French Lab Salicylamides and compositions thereof
US4009174A (en) 1972-12-08 1977-02-22 The Boots Company Limited Esters of substituted nicotinic acids
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
JPS5734314B2 (en) 1973-12-22 1982-07-22
GB1561350A (en) 1976-11-05 1980-02-20 May & Baker Ltd Benzamide derivatives
FR2344284A1 (en) 1976-03-17 1977-10-14 Cerm Cent Europ Rech Mauvernay NEW TRICYCLIC COMPOUNDS WITH A FURANNIC CYCLE AND THEIR APPLICATION AS ANTIDEPRESSANTS
GB1588242A (en) 1977-10-28 1981-04-23 May & Baker Ltd N-(tetrazol-5-yl)-salicylamide derivatives
US4474792A (en) * 1979-06-18 1984-10-02 Riker Laboratories, Inc. N-Tetrazolyl benzamides and anti-allergic use thereof
JPS5721320A (en) 1980-07-11 1982-02-04 Chugai Pharmaceut Co Ltd Blood sugar level depressing agent
JPS5775962A (en) 1980-10-29 1982-05-12 Shionogi & Co Ltd 2-alkoxybenzamide derivative
FR2493848B2 (en) 1980-11-07 1986-05-16 Delalande Sa NOVEL NOR-TROPANE AND GRANATANE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION
JPS5869812A (en) 1981-10-22 1983-04-26 Chugai Pharmaceut Co Ltd Blood sugar level depressing agent
JPS59139357A (en) 1983-01-28 1984-08-10 Torii Yakuhin Kk Amidine derivative
JPS61205937A (en) 1985-03-09 1986-09-12 Konishiroku Photo Ind Co Ltd Silver halide color photographic sensitive material
JPS62142168A (en) 1985-10-16 1987-06-25 Mitsubishi Chem Ind Ltd Thiazole derivatives and leukotriene anti-inflammatory agents containing them as active ingredients
JPS62158252A (en) * 1985-12-28 1987-07-14 Kirin Brewery Co Ltd 4-aminopyridinebenzamide derivative
CA1327358C (en) 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
JP2852659B2 (en) 1988-03-03 1999-02-03 富山化学工業株式会社 Piperazine derivatives and their salts
DE3822449A1 (en) 1988-07-02 1990-01-04 Henkel Kgaa OXIDATION HAIR AGENT WITH NEW COUPLERS
JPH03181465A (en) 1989-12-11 1991-08-07 Takeda Chem Ind Ltd Quinoline derivative
JPH04300832A (en) 1991-03-29 1992-10-23 Tsumura & Co Leukotriene antagonistic agent containing 2,4-diamino-1,3,5-triazine derivative as active ingredient
JPH04300874A (en) 1991-03-29 1992-10-23 Tsumura & Co New 2,4-diamino-1,3,5-triazine derivative
US5258407A (en) 1991-12-31 1993-11-02 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5466715A (en) 1991-12-31 1995-11-14 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5273986A (en) 1992-07-02 1993-12-28 Hoffmann-La Roche Inc. Cycloalkylthiazoles
JPH0627025A (en) 1992-07-06 1994-02-04 Toto Ltd Molecule recognizing function film and sensor employing it
WO1994004525A1 (en) 1992-08-20 1994-03-03 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds as oxytocin and vasopressin antagonists
AU673569B2 (en) 1992-12-02 1996-11-14 Pfizer Inc. Catechol diethers as selective PDE-IV inhibitors
EP0619116A3 (en) 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
GB9307527D0 (en) 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
WO1995006034A1 (en) 1993-08-24 1995-03-02 Medivir Ab Compounds and methods for inhibition of hiv and related viruses
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
AU680370B2 (en) 1994-06-21 1997-07-24 Otsuka Pharmaceutical Factory, Inc. Pyrazolo(1,5-a)pyrimidine derivative
US5661153A (en) 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
US5792109A (en) 1994-09-01 1998-08-11 Leland L. Ladd Irrigation pump and system
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
JPH08143565A (en) 1994-11-16 1996-06-04 Fujisawa Pharmaceut Co Ltd Benzamide compound
US5510478A (en) * 1994-11-30 1996-04-23 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5672750A (en) * 1994-12-16 1997-09-30 Eastman Chemical Company Preparation of aromatic amides from carbon monoxide, an amine and an aromatic chloride
JP2930731B2 (en) 1994-12-20 1999-08-03 エフ・ホフマン−ラ ロシュ アーゲー Aryl- and heteroaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5849735A (en) * 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5536718A (en) 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5696112A (en) 1995-01-17 1997-12-09 American Cyanamid Company Fused heterocyclic azepines as vasopressin antagonists
US5700796A (en) 1995-01-17 1997-12-23 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5532235A (en) 1995-01-17 1996-07-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AR002459A1 (en) 1995-01-17 1998-03-25 American Cyanamid Co TRASCINIC BENZACEPINE VASOPRESIN ANTAGONISTS, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM, A METHOD FOR TREATING DISEASES AND A PROCEDURE FOR THEIR PREPARATION.
JPH08301760A (en) * 1995-05-10 1996-11-19 Shiseido Co Ltd Skin preparation for external use
KR100424933B1 (en) 1995-05-18 2004-07-27 제리아 신야쿠 고교 가부시키 가이샤 Aminothiazole derivatives, medicaments containing them and intermediates of the compounds
JP3168915B2 (en) 1995-05-25 2001-05-21 田辺製薬株式会社 Pharmaceutical composition
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
US5712270A (en) * 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
JP3735741B2 (en) 1995-11-24 2006-01-18 株式会社大塚製薬工場 Fused pyrimidine derivative
GB9526558D0 (en) 1995-12-27 1996-02-28 Fujisawa Pharmaceutical Co Heterobicyclic derivatives
IL126318A (en) 1996-03-29 2004-09-27 Emisphere Tech Inc Compounds and compositions for delivering active agents and some novel carrier compounds
CA2257222C (en) 1996-06-06 2002-08-20 Otsuka Pharmaceutical Factory, Inc. Amide derivatives
JPH10101672A (en) 1996-08-06 1998-04-21 Otsuka Pharmaceut Factory Inc Adenosine enhancer
JPH10101671A (en) 1996-08-08 1998-04-21 Otsuka Pharmaceut Factory Inc Nitric oxide synthase inhibitor
AUPO395396A0 (en) 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
FR2757852B1 (en) 1996-12-31 1999-02-19 Cird Galderma STILBENIC COMPOUNDS WITH ADAMANTYL GROUP, COMPOSITIONS CONTAINING SAME, AND USES
JPH10212271A (en) 1997-01-31 1998-08-11 Zeria Pharmaceut Co Ltd N-substituted benzoylamine derivatives, medicaments containing them and intermediates for the production of said compounds
JP4975201B2 (en) 1997-02-07 2012-07-11 エミスフェアー・テクノロジーズ・インク Compositions for delivering compounds and active agents
JPH10338658A (en) 1997-04-08 1998-12-22 Hoechst Marion Roussel Kk Retinoid action regulator
JPH1129480A (en) 1997-05-12 1999-02-02 Otsuka Pharmaceut Factory Inc Pharmaceutical composition containing fused pyrimidine derivative
CN1268942A (en) 1997-06-27 2000-10-04 藤泽药品工业株式会社 Sulfonamide compounds and medicinal use thereof
EP1000932B9 (en) 1997-06-27 2005-12-28 Fujisawa Pharmaceutical Co., Ltd. Aromatic ring derivatives
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6114483A (en) 1997-08-27 2000-09-05 E. I. Du Pont De Nemours And Company Polymerization of olefins
JPH11171848A (en) 1997-09-26 1999-06-29 Fujirebio Inc Aromatic amide derivative
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DE69801590T2 (en) 1997-10-22 2002-07-11 Astrazeneca Ab, Soedertaelje IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS
JP4398585B2 (en) 1997-11-12 2010-01-13 有限会社ケムフィズ Retinoid receptor agonist
EP1042320B1 (en) 1997-11-21 2002-02-13 AstraZeneca UK Limited New compounds which are p2-purinoceptor 7-transmembrane (tm) g-protein coupled receptor antagonists
GB9725298D0 (en) 1997-11-28 1998-01-28 Zeneca Ltd Insecticidal thiazole derivatives
IL135536A0 (en) 1997-12-19 2001-05-20 Schering Ag Ortho-anthranilamide derivatives and pharmaceutical compositions containing the same
JP4253126B2 (en) 1998-01-29 2009-04-08 アムジェン インコーポレイテッド PPAR-gamma modulator
JP3937367B2 (en) 1998-02-05 2007-06-27 株式会社大塚製薬工場 Nitric oxide synthase inhibitor
JPH11292879A (en) * 1998-04-08 1999-10-26 Otsuka Pharmaceut Factory Inc Carboxamide derivative
DE19816780A1 (en) 1998-04-16 1999-10-21 Bayer Ag New tryptamine derivatives useful as antibacterial agents for treating infections in humans and especially animals
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
DE19830431A1 (en) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Sulfonylamino-carboxylic acid N-arylamides as guanylate cyclase activators
US6197798B1 (en) 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
JP4191825B2 (en) 1998-09-10 2008-12-03 あすか製薬株式会社 5-aminoisoxazole derivatives
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
DE69919212T2 (en) * 1998-12-23 2005-07-28 Eli Lilly And Co., Indianapolis AROMATIC AMIDES
EP1150955A2 (en) 1999-02-04 2001-11-07 Millennium Pharmaceuticals, Inc. G-protein coupled heptahelical receptor binding compounds and methods of use thereof
HUP0200396A3 (en) * 1999-03-29 2003-04-28 Hoffmann La Roche Gluckokinase activators, process for their preparation, pharmaceutical compositions containing them and their use
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
US6610846B1 (en) * 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
RU2242469C2 (en) * 1999-03-29 2004-12-20 Ф.Хоффманн-Ля Рош Аг Glucokinase activating agents
MXPA01013199A (en) 1999-06-30 2003-08-20 Tularik Inc COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY.
CA2381882C (en) 1999-08-13 2011-01-25 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
DE60023920T2 (en) 1999-08-27 2006-07-20 Sugen, Inc., South San Francisco Phosphate mimetics and methods of treatment with phosphatase inhibitors HIBITORS
GB9921684D0 (en) 1999-09-15 1999-11-17 Zeneca Ltd Assays
BR0014076A (en) * 1999-09-17 2002-10-15 Millennium Pharm Inc Benzamides and related factor xa inhibitors
EP1225894B1 (en) 1999-10-08 2006-07-05 Affinium Pharmaceuticals, Inc. Fab i inhibitors
BR0015299A (en) 1999-11-04 2003-04-15 Johnson & Johnson Nonpeptide substituted benzothiazepines as vasopressin antagonists
WO2001035950A2 (en) * 1999-11-18 2001-05-25 Centaur Pharmaceuticals, Inc. Benzamide therapeutics and methods for treating inflammatory bowel disease
US6353111B1 (en) * 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
AU2001245353A1 (en) * 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
EP1132381A1 (en) 2000-03-08 2001-09-12 Cermol S.A. Ester derivatives of dimethylpropionic acid and pharmaceutical compositions containing them
AU776053B2 (en) 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
EP1280801B1 (en) 2000-05-03 2005-09-07 F. Hoffmann-La Roche Ag Hydantoin-containing glucokinase activators
AU2001270494B2 (en) * 2000-05-03 2005-11-10 F. Hoffmann-La Roche Ag Alkynyl phenyl heteroaromatic glucokinase activators
PT1283830E (en) 2000-05-08 2008-08-18 Hoffmann La Roche Para-amine substituted phenylamide glucokinase activators
EP1282611B1 (en) 2000-05-08 2004-10-20 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
EA005976B1 (en) 2000-06-28 2005-08-25 Туларик Инк. Quinolinyl and benzothiazolyl ppar-gamma modulators
WO2002008209A1 (en) 2000-07-20 2002-01-31 F. Hoffmann-La Roche Ag Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
US6369232B1 (en) 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
US7053105B2 (en) 2000-09-25 2006-05-30 Janssen Pharmaceutica, N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
AU2002211281A1 (en) 2000-09-29 2002-04-08 Millenium Pharmaceuticals, Inc. Quaternary amidino based inhibitors of factor xa
AU2002214546A1 (en) 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Bicyclic pyrimidin-4-one based inhibitors of factor xa
CA2425097A1 (en) 2000-10-05 2002-04-11 Fujisawa Pharmaceutical Co., Ltd. Benzamide compounds as apo b secretion inhibitors
HUP0400558A3 (en) 2000-11-22 2010-03-29 Astellas Pharma Inc Substituted benzene derivatives or salts thereof and pharmaceutical compositions containing them
ATE316965T1 (en) 2000-12-06 2006-02-15 Hoffmann La Roche CONDENSED HETEROAROMATIC GLUCOCINASE ACTIVATORS
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
CN1289072C (en) 2000-12-22 2006-12-13 石原产业株式会社 Aniline derivatives or salts thereof and cytokine prodn inhibitors contg. same
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
JPWO2002062775A1 (en) * 2001-02-02 2004-06-10 山之内製薬株式会社 2-acylaminothiazole derivative or salt thereof
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
ATE368643T1 (en) 2001-03-30 2007-08-15 Millennium Pharm Inc FACTOR XA BENZAMIDINE INHIBITORS
SE0102299D0 (en) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102300D0 (en) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
WO2003016254A1 (en) 2001-08-09 2003-02-27 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
TWI325302B (en) 2001-08-13 2010-06-01 Du Pont Benzoxazinone compounds
SE0102764D0 (en) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
WO2003022856A1 (en) 2001-09-12 2003-03-20 Pharmacia & Upjohn Company Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases
TW200724033A (en) 2001-09-21 2007-07-01 Du Pont Anthranilamide arthropodicide treatment
UA78232C2 (en) 2001-09-21 2007-03-15 Брістол-Майерс Сквібб Компані Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CA2460594A1 (en) 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Mch receptor antagonists
EP1336607A1 (en) 2002-02-19 2003-08-20 Novo Nordisk A/S Amide derivatives as glucokinase activators
EP1453541A1 (en) 2001-12-03 2004-09-08 Novo Nordisk A/S Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
WO2003048152A2 (en) 2001-12-05 2003-06-12 Tularik Inc. Inflammation modulators
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US6911545B2 (en) 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
PL370989A1 (en) 2001-12-21 2005-06-13 Novo Nordisk A/S Amide derivatives as gk activators
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
JP4419571B2 (en) 2002-03-26 2010-02-24 萬有製薬株式会社 New aminobenzamide derivatives
CN100357283C (en) 2002-04-02 2007-12-26 中国科学院上海药物研究所 Methionyl aminopeptidase inhibitor
RS93604A (en) 2002-04-26 2007-02-05 F. Hoffmann-La Roche Ag., Substituted phenylacetamides and their use as glucokinase activators
WO2003097824A1 (en) 2002-05-16 2003-11-27 Banyu Pharmaceutical Co., Ltd. Crystal of glucokinase protein, and method for drug design using the crystal
MXPA05000130A (en) 2002-06-27 2005-02-17 Novo Nordisk As Aryl carbonyl derivatives as therapeutic agents.
US20060004010A1 (en) 2002-07-10 2006-01-05 Hiromu Habashita Ccr4 antagonist and medical use thereof
WO2004022536A1 (en) 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
ATE374768T1 (en) 2002-10-03 2007-10-15 Hoffmann La Roche INDOLE-3-CARBONIC ACID AMIDES AS GLUCOKINASE (GK) ACTIVATORS
JP2006509774A (en) 2002-10-03 2006-03-23 ノバルティス アクチエンゲゼルシャフト Substituted (thiazol-2-yl) -amides or sulfonamides as glucokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
CA2509086C (en) 2003-01-06 2012-08-21 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
AU2003294376A1 (en) 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
EP1594863A1 (en) 2003-02-11 2005-11-16 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (en) 2003-02-11 2006-03-06 Prosidion Limited Tri(cyclo) substituted amide compounds
AR045414A1 (en) 2003-02-13 2005-10-26 Banyu Pharma Co Ltd DERIVATIVES OF 2 - PIRIDINCARBOXAMIDA AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
NZ541824A (en) 2003-02-26 2010-04-30 Banyu Pharma Co Ltd Heteroarylcarbamoylbenzene derivatives as glucokinase activators
AR043633A1 (en) 2003-03-20 2005-08-03 Schering Corp CANABINOID RECEIVERS LINKS
KR20050119652A (en) 2003-03-24 2005-12-21 에프. 호프만-라 로슈 아게 Benzyl-pyridazinons as reverse transcriptase inhibitors
MXPA05012281A (en) 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compouds and uses thereof in modulating amyloid beta.
US20070099884A1 (en) 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
GB0325402D0 (en) 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
WO2005048953A2 (en) 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0327760D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0328178D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
RU2329261C2 (en) 2003-12-29 2008-07-20 Баниу Фармасьютикал Ко., Лтд. New 2-heteroaryl-substitute benzimidazole derivative
PL1723128T3 (en) 2004-01-06 2013-04-30 Novo Nordisk As Heteroaryl-ureas and their use as glucokinase activators
RU2392275C2 (en) 2004-02-18 2010-06-20 Астразенека Аб Benzamide derivatives and application as glucokinase activation agents
US20080312207A1 (en) 2004-02-18 2008-12-18 Craig Johnstone Compounds
US7687502B2 (en) 2004-03-23 2010-03-30 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
BRPI0509573A (en) 2004-04-02 2007-09-25 Novartis Ag sulfonamide thiazolpyridine derivatives as useful glucokinase activators for the treatment of type 2 diabetes
BRPI0509543A (en) 2004-04-02 2007-09-18 Novartis Ag thiazolopyridine derivatives, pharmaceutical conditions containing them and methods for treating glucokinase-mediated conditions
AU2005235798A1 (en) 2004-04-21 2005-11-03 Prosidion Limited Tri(cyclo) substituted amide compounds
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
JP2008502658A (en) 2004-06-17 2008-01-31 ノボ　ノルディスク　アクティーゼルスカブ Use of liver-selective glucokinase activator
WO2006016194A1 (en) 2004-08-12 2006-02-16 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
GB0418046D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
GB0418058D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
GB0423043D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
US7700640B2 (en) 2004-10-16 2010-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
GB0423044D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
US7890092B2 (en) 2004-12-24 2011-02-15 Telecom Italia S.P.A. Method of optimising web page access in wireless networks
JP5033119B2 (en) 2005-04-25 2012-09-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel azaheterocycles as kinase inhibitors
US20110059941A1 (en) 2005-05-24 2011-03-10 Peter William Rodney Caulkett 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
EP1910350A1 (en) 2005-07-09 2008-04-16 AstraZeneca AB 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
JP4651714B2 (en) 2005-07-09 2011-03-16 アストラゼネカ アクチボラグ Heteroarylbenzamide derivatives for use as GLK activators in the treatment of diabetes
EP2027113A1 (en) 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
WO2007017649A1 (en) 2005-08-09 2007-02-15 Astrazeneca Ab Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
JP2007063225A (en) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd Imidazopyridine compound
US20090105263A1 (en) 2005-09-16 2009-04-23 Peter William Rodney Caulkett Heterobicyclic compounds as glucokinase activators
CA2627813A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
CL2007003061A1 (en) 2006-10-26 2008-08-01 Astrazeneca Ab COMPOUNDS DERIVED FROM 3,5-DIOXI-BENZAMIDA; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT A MEDIUM DISEASE THROUGH GLK, SUCH AS TYPE 2 DIABETES.
JP2010513445A (en) 2006-12-21 2010-04-30 アストラゼネカ アクチボラグ Novel crystalline compounds useful as GLK activators

Also Published As

Publication number Publication date
ATE407672T1 (en) 2008-09-15
EP1674097A1 (en) 2006-06-28
WO2003015774A1 (en) 2003-02-27
DE60213678D1 (en) 2006-09-14
EP1661567B1 (en) 2008-06-11
PT1661569E (en) 2008-08-18
ES2312050T3 (en) 2009-02-16
DE60228897D1 (en) 2008-10-23
RU2329043C9 (en) 2008-11-20
CY1108276T1 (en) 2014-02-12
DE60226914D1 (en) 2008-07-10
DE60213678T2 (en) 2007-08-09
ATE396720T1 (en) 2008-06-15
PT1529530E (en) 2006-11-30
CN101704797A (en) 2010-05-12
HK1079692A1 (en) 2006-04-13
TWI333855B (en) 2010-12-01
HK1093429A1 (en) 2007-03-02
EP1661569A1 (en) 2006-05-31
JP2005525291A (en) 2005-08-25
ES2309862T3 (en) 2008-12-16
EP1669069B1 (en) 2008-09-10
EP1529530B1 (en) 2006-08-02
ZA200401015B (en) 2005-05-06
ES2307238T3 (en) 2008-11-16
JP2005320343A (en) 2005-11-17
US7390908B2 (en) 2008-06-24
CY1105746T1 (en) 2010-12-22
US20050080106A1 (en) 2005-04-14
DK1529530T5 (en) 2009-11-23
ATE406891T1 (en) 2008-09-15
CN101492416B (en) 2012-02-22
PT1568367E (en) 2007-06-28
HK1090291A1 (en) 2006-12-22
DE60219698T2 (en) 2007-12-27
DE60227122D1 (en) 2008-07-24
DK1661569T3 (en) 2008-09-15
SI1529530T1 (en) 2006-12-31
IL203923A (en) 2013-03-24
CA2457410C (en) 2011-09-27
EP1669068A1 (en) 2006-06-14
CN100577163C (en) 2010-01-06
EP1669069A1 (en) 2006-06-14
DE60227120D1 (en) 2008-07-24
CY1107683T1 (en) 2013-04-18
CY1108254T1 (en) 2014-02-12
IS7150A (en) 2004-02-13
RU2004104333A (en) 2005-03-27
CN1568185A (en) 2005-01-19
CY1108267T1 (en) 2014-02-12
EP1695705A1 (en) 2006-08-30
AR037898A1 (en) 2004-12-22
DE60213678T3 (en) 2010-02-25
HK1089960A1 (en) 2006-12-15
DE60210782D1 (en) 2006-05-24
ES2285341T7 (en) 2010-03-31
CN101584691A (en) 2009-11-25
US7524957B2 (en) 2009-04-28
EP1420784A1 (en) 2004-05-26
BR0212008A (en) 2004-09-28
IL160219A0 (en) 2004-07-25
HK1089958A1 (en) 2006-12-15
US20090227592A1 (en) 2009-09-10
HK1090839A1 (en) 2007-01-05
ES2270263T7 (en) 2010-03-31
DE60227121D1 (en) 2008-07-24
SI1568367T1 (en) 2007-08-31
SI1661569T1 (en) 2008-10-31
ES2285341T3 (en) 2007-11-16
EP1529530A1 (en) 2005-05-11
ATE334678T1 (en) 2006-08-15
AU2002321462B2 (en) 2007-09-20
EP1661567A1 (en) 2006-05-31
EP1661563B1 (en) 2008-05-28
US20080207636A1 (en) 2008-08-28
DE60228770D1 (en) 2008-10-16
TW200911238A (en) 2009-03-16
EP1568367B1 (en) 2007-04-18
ATE359781T1 (en) 2007-05-15
SE0102764D0 (en) 2001-08-17
HK1089966A1 (en) 2006-12-15
KR100920439B1 (en) 2009-10-08
EP1987831A1 (en) 2008-11-05
ATE323487T1 (en) 2006-05-15
US7951830B2 (en) 2011-05-31
ES2306300T3 (en) 2008-11-01
EP1568367B3 (en) 2009-09-02
ES2307239T3 (en) 2008-11-16
DK1661563T3 (en) 2008-08-25
HK1076042A1 (en) 2006-01-06
DK1568367T5 (en) 2009-11-23
CN101492416A (en) 2009-07-29
CO5560563A2 (en) 2005-09-30
DE60228143D1 (en) 2008-09-18
DK1568367T3 (en) 2007-07-30
ATE397927T1 (en) 2008-07-15
KR20040030125A (en) 2004-04-08
HK1090292A1 (en) 2006-12-22
ATE397926T1 (en) 2008-07-15
ES2270263T3 (en) 2007-04-01
DE60219698D1 (en) 2007-05-31
MY146279A (en) 2012-07-31
EP1695705B1 (en) 2008-08-06
ATE403427T1 (en) 2008-08-15
ES2312051T3 (en) 2009-02-16
DE60210782T2 (en) 2007-05-10
CA2457410A1 (en) 2003-02-27
SI1669068T1 (en) 2008-10-31
EP1661569B1 (en) 2008-06-11
HUP0401213A2 (en) 2004-12-28
JP4441446B2 (en) 2010-03-31
NO20040686L (en) 2004-02-17
EP1568367A1 (en) 2005-08-31
EP1661568B1 (en) 2008-09-03
ATE397929T1 (en) 2008-07-15
RU2329043C2 (en) 2008-07-20
ATE397928T1 (en) 2008-07-15
HK1064598A1 (en) 2005-02-04
EP1674097B1 (en) 2008-06-11
EP1661568A1 (en) 2006-05-31
HUP0401213A3 (en) 2011-03-28
EP1669068B1 (en) 2008-06-11
UA83182C2 (en) 2008-06-25
ES2308609T3 (en) 2008-12-01
PL368970A1 (en) 2005-04-04
ES2307237T3 (en) 2008-11-16
SI1661563T1 (en) 2008-10-31
PT1661563E (en) 2008-07-31
JP3987829B2 (en) 2007-10-10
DK1669068T3 (en) 2008-09-22
EP1529530B3 (en) 2009-09-02
NZ531193A (en) 2005-07-29
DE60227119D1 (en) 2008-07-24
MXPA04001500A (en) 2004-05-14
EP1420784B1 (en) 2006-04-19
DK1529530T3 (en) 2006-11-13
DE60219698T3 (en) 2010-02-25
EP1661563A1 (en) 2006-05-31

Similar Documents

Publication Publication Date Title
IL160219A0 (en) Compounds effecting glucokinase
AU2002349297A8 (en) Statin-like compounds
GB0101996D0 (en) Organtic compounds
GB0102668D0 (en) Compounds
GB0130335D0 (en) Compounds
GB0112324D0 (en) Compounds
PL365107A1 (en) Compounds
GB0102665D0 (en) Compounds
GB0108102D0 (en) Compounds
GB0102673D0 (en) Compounds
GB0115178D0 (en) Compounds
GB0108097D0 (en) Compounds
GB0105098D0 (en) Compounds
GB0101629D0 (en) Compounds
GB0104399D0 (en) Compounds
GB0100183D0 (en) Vovel compounds
GB0100652D0 (en) Polysulfamated compounds
GB0101628D0 (en) Compounds
GB0126723D0 (en) Compounds
GB0102661D0 (en) Compounds
GB0126431D0 (en) Compounds
GB0102670D0 (en) Compounds
GB0121303D0 (en) Compounds
GB0103314D0 (en) Compounds
GB0104396D0 (en) Compounds